Considerations for Medication Management in Older Adults with Multi-morbidity

Presenters:

Dr. Rae Petrucha Julia Bareham

October 15, 2019

Speaker Bios

Rae Petrucha

- Family physician at West Winds Primary Health Centre
- Academic teaching unit at West Winds Care of the Elderly; focus on providing optimal care in the community setting (Long Term Care & Personal Care Homes)

Julia Bareham

- Pharmacist with RxFiles Academic Detailing
- RxFiles primarily related to medication use in older adults
- Community pharmacy; MSc comprehensive medication management





Presenter Disclosure

Relationships with financial sponsors:

- Rae Petrucha contracted with West Winds Primary Health Centre (CoM)
- Julia Bareham employee of RxFiles Academic Detailing (U of S) & Shoppers Drug Mart; Drug and Therapeutic Advisory Committee for Non-Insured Health Benefits – Indigenous Services Canada

Speakers have received <u>no additional financial support</u> for the preparation or delivery of the presentation

- Rae Petrucha has no conflicts of interest to declare
- Julia Bareham conflict/bias: works for RxFiles sells a product that will be discussed during the presentation

What is RxFiles?

GERI-RXFILES 3RD EDITION

ASSESSING MEDICATIONS IN OLDER ADULTS

Alternatives to explore, when less may be more

Academic detailing program providing objective, comparative drug information to clinicians.

www.rxfiles.ca

julia@rxfiles.ca





Learning Objectives



Identify considerations & approaches that may be used when prescribing to older adults



Discuss methods to prioritize & optimize medication use in the presence of polypharmacy & multimorbidity in older adults in the primary care setting



Apply the principles of geriatric prescribing as it relates to sedatives, antihypertensives and anticholinergics to patient cases

Drug Therapy in Older Adults

- Definition of "Older Adult"
- Consider overall frailty & physiological age more prominently than chronological age when applying geriatric models to care
- Few RCTs include individuals >80, especially for those with multiple comorbidities
- Individualization of approach, clinical judgement & special consideration for principles of geriatric care are critical!

Prescribing Considerations for Older Adults

Special Considerations in Geriatrics –

What to consider when there is no/limited evidence when it comes to decision making

- Older adults can be challenging & time consuming to adequately assess & treat due to multimorbidity, polypharmacy, provider time constraints, etc.
- They are complex!
- Making the decision to prescribe or not prescribe takes time.
 Navigate those discussions/decisions
- Consider more frequent visits and discuss one issue at a time



Physiological Changes



Polypharmacy & Co-morbidities



Limited Life Expectancy & Time-to-Benefit



Quality of Life Considerations



Personal Values & Shared Decision Making

Challenges related to regular	
medication use	

_	1
•	•

Cost of medications/interventions

Tips:

- Look/think beyond the clinical interaction at the moment or the Rx
 → need a wholistic approach.
- Consider the social aspect!
 - Cognitive decline with lack of social engagement

Assessing Medications: Harm vs Benefit

• Beece Percentiaria (complemented by the START Criteria)

Section A: Indication of medication

- 1. Any drug prescribed without an evidence-based clinical indication.
- Any drug prescribed beyond the recommended duration, where treatment duration is well defined.
- Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent).

Section B: Cardiovascular System

- Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit).
- 2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure).

Patient Snapshot – 68 yr old Martha


- Naproxen 220mg BID
- Furosemide 20mg OD
- Amlodipine 5mg OD
- Allopurinol 200mg OD
- Metformin 500mg BID
- Atorvastatin 10mg OD

- Arthritis
- T2DM
- Dyslipidemia
- HTN
- Edema (Ankle swelling)
- Gout

Prescribing Cascades

Definition:

The prescribing of a new medication to treat symptoms that have arisen from an unrecognized adverse drug event related to an existing therapy.



Medications Commonly Involved in Prescribing Cascades

ANTIBIOTICS ANTIPSYCHOTICS • NITRATES ullet**ANTIEPILEPTICS** • ACETYLCHOLINESTERASE • NSAIDS ightarrow**INHIBITORS** • OPIOIDS **ANTIHYPERTENSIVES** igodol• DIGOXIN ACEIS βΒS • PAROXETINE CCBS • METOCLOPRAMIDE DIURETICS • SEDATIVES

ANTICHOLINERGICS?

Preventing the Prescribing Cascade Assume every new symptom is due to a drug until proven otherwise.

Look for opportunities to deprescribe!

Preventing the Prescribing Cascade

Start low, go slow.

Did the symptoms started after a new medication was initiated/ dose change

Pt education

Document clearly when & why a medication is stopped or started

Encourage patients/residents to keep an up-to-date list of meds Always consider potential drug-drug or drug-disease interactions when starting new meds.



The official journal of the College of Family Physicians of Canada

Home	Articles	Info for	About CFP	Feedback	Blogs
Other Bractice					

Other | Practice

Problem-based deprescribing

Using your patients' clinical concerns to guide medication review

Frank Molnar and Chris Frank Canadian Family Physician April 2019, 65 (4) 266;



The official journal of the College of Family Physicians of Canada

Home	Articles	Info for	About CFP	Feedback		
Article Comment	ary Commentary					
Choosin	Choosing wisely					
Avoiding to	Avoiding too much medicine					
Bartosz Hudzik, Michal Hudzik and Lech Polonski Canadian Family Physician October 2014, 60 (10) 873-876;						

CANADIAN FAMILY PHYSICIAN • LE MÉDECIN DE FAMILLE CANADIEN The official journal of the College of Family Physicians of Canada					search	Q Advanced Search	
Home	Articles	Info for	About CFP	Feedback	Blogs	Mainpro+ Credits	
Research Article	Research						

Effect of comorbidities and medications on frequency of primary care visits among older patients

Tina Hu, Neil D. Dattani, Kelly Anne Cox, Bonnie Au, Leo Xu, Don Melady, Liisa Jaakkimainen, Rahul Jain and Jocelyn Charles Canadian Family Physician January 2017, 63 (1) 45-50;

Considerations for Deprescribing

What is deprescribing?

• The process of withdrawing medications in an attempt to improve patient outcomes. Deprescribing should be considered during every regular review of a patient. It is particularly important among older people in whom multimorbidity and polypharmacy are common.

What are the risks of deprescribing?

- Withdrawal reactions
 - e.g. GI symptoms & insomnia when stopping SSRIs
- Rebound phenomena
 - e.g. tachycardia when stopping beta-blocker
 - Does it need to be tapered? See the Geri-RxFiles!
- Reappearance of symptoms
 - e.g. pain when NSAID/opioid stopped



Practical Tips/Ideas

A) A good medication review is essential!!!

B) Deprescribe.

C) One medication change at a time.

D) Explain the rationale for the medication change.

E) Plan to assess after medication changes are made whether the target symptom (or parameter) got better or worse.

F) Be watchful for unmasked drug interactions.

G) Start medications that are missing & will be of benefit.

H) Use a team approach. Communicate. Make use of each team members' unique skill set.

Question....

Tomorrow, after watching this presentation, when you're in clinic and you have a routine visit with a 75 year old patient who is there to see you for her prescription renewal. What would be a good 'first step' to ensure you've touched on the foundational steps for optimizing care for this patient?

- A) Ensure your patient is taking the appropriate medications doses for her age, health status, etc. and renew the prescription. Have the patient rebook for follow-up the following week.
- B) Take the opportunity to ask about her spouse who is not present at today's visit, but usually attends, and is also a patient of yours. He appeared frailer at your last appointment.

C) Discuss goals of therapy and explore shared-decision making.

D) Refer your patient to geriatric assessment for a full assessment.

- 83 year old female "Elsa"
- new to your practice
- oxazepam 10mg PO QHS x ~30 yrs
- too tired to manage all of the routine household chores that she is accustomed to doing independently, and that she derives great satisfaction in completing
- dosing off if she is sitting quietly doing an activity (watching TV, knitting) throughout the day
- no difficulty with initiating sleep or with waking throughout the night

Shared-Decision Making & Educating Patients About the Risks vs Benefits

What are the potential harms of benzodiazepines in older adults?

Potential Harms & Benefits of BZDs

Harms of sedative hypnotics (BZD & non-BZD)	Benefits
Risk of rebound insomnia	Improve short-term ^(up to 6 weeks) sleep
 Development of tolerance, dependence & withdrawal reactions Residual daytime sedation Risk of falls, fractures & cognitive impairment Risk of accidents (e.g. MVAs) 	 outcomes modestly: ↓ sleep onset by 10 to 20 minutes ↑ total sleep time by ~30 minutes ↓ # of awakening by ~ 0.6

Treating 13 patients with a sedative hypnotic (BZD or Z-drug) for insomnia will improve sleep quality in 1 patient but 2 patients will likely experience with adverse effects (5 days to 9 weeks).

Potential Harms & Benefits of BZDs

BZD Long-term effects on sleep:

- 76 middle-aged & elderly chronic insomniacs using low-dose benzodiazepines (LDB),minimum of 6 months VS drug-free insomniacs to determine the effect on sleep.
- Results showed that LDB leads to a complete loss of hypnotic activity & substantial suppression of delta & REM sleep.

Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand. 1988 Dec;78(6):706-11. PubMed PMID: 2906215.



• For those 18-64 years of age (weak recommendation from systematic review and GRADE approach)

liazepine receptor agonists. Can Fam Physician 2018;64:339-51 (Eng), e209-24 (

If symptoms relapse:

Alternate drugs

🔿 deprescribing.org Bruvère 👌

continue to taper at slow rate

This algorithm and accompanying advice support recommendations in the NICE guidance on the use of zalepion, zoipidem and zopicione for the short-term management of insomnia, and medicines optimisation. National institute for health and Care Excellence, February 2019

Maintaining current BZRA dose for 1-2 weeks, then

effectiveness is beyond the scope of this algorithm.

ODGU

Other medications have been used to manage

See BZRA deprescribing guideline for details.

insomnia. Assessment of their safety and

Consider

Use non-drug

approaches to

Use behavioral

approaches

(see reverse)

and/or CBT

manage

insomnia

Offer behavioural sleeping advice; consider CBT if available (see reverse)

Monitor every 1-2 weeks for duration of tapering

♥ Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission. (○))) This work is licensed under a Creative Commons Attribution-NonCommercial-ShareNike 4.0 International License Contact - Speecer Change Duryer, and a creative Commons of the Community of the C

· May improve alertness, cognition, daytime sedation and reduce falls

· Insomnia, anxiety, irritability, sweating, gastrointestinal symptoms

(all usually mild and last for days to a few weeks)

Expected benefits:

Withdrawal symptoms:

Objective To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review; and endorsement processes.

Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvolting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing tratas and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline.

Recommendations This guideline recommends deprescribing PPIs (reducing dose, stopping, or



-

e Print	- Share
📥 Download PDF	y Tweet
Article Alerts	u Like 0
Semail Article	
Citation Tools	
Respond to this article	
Jump to section	
O Articla	

· · · ·

Article
 Abstract



You May Be at Risk

You are taking one of the following sedative-hypnotic medications:



Tapering-off program

Be sure to talk to your doctor, nurse or pharmacist before you try reducing your dose or stopping your medication.



Back to the patient case....

We discussed risks of the medication (impacts on cognition, falls, increased daytime somnolence) while taking the patient's preference into consideration.

Patient unwilling to titrate off completely, but open to reducing dose.

Gradual reduction in dose, taper is currently ongoing, but now down to oxazepam 5mg PO QHS.

Patient has a lot more energy throughout the day, is able to complete all of her housework, and is no longer falling asleep. Since she is feeling so much better she would like to see how she feels at an even lower dose.

Question....

A 96-year-old female patient of yours presents to you in clinic requesting a refill of her long-standing prescriptions of quetiapine and lorazepam that she is unwilling to discontinue. Which response to her request would you likely provide?

- A) Refill her prescription. She has been taking them for years without any problems.
- B) Explain the risks to her and document your discussion.
- C) Discontinue the medications. They are risky in older adults.
- D) Offer a non-pharmacological alternative to the medications such as CBTi since she is using the meds for sleep.

Patient Case #2 - Antihypertensives

- 93 year old female "Anna"; new to your practice.
- Living in a personal care home for several years, and has not been to see a physician for at least a decade.
- The personal care home operator notes that she is quite fatigued most of the time and doesn't really participate in activities within the home. No complaints of pain.
- Rockwood Frailty score of 7
- No BPs measured since living in the personal care home (~10 years)
- Review of her medication list shows that she is currently taking:
 - α-methyldopa 500mg PO BID
 - Naproxen 500mg PO BID
 - Acetaminophen 500mg PO BID PRN

Hypertension in Older Adults

- Need to look at systolic & diastolic
- May need to tolerate higher systolic in order to maintain diastolic >60mmHg to ensure adequate cardiac perfusion
 ↑ risk with ↓ diastolic
- Multimorbidity makes it challenging to find the ideal treatment/target. Does the pt have T2DM but is also on an anticoagulant? How far do we push the target?
- Balance the harms vs the risks!

	Population	Office Blood Pressure (mmHg) Threshold to treat with antihypertensive(s)	Blood Pressure Ta	rget (mmHg)	
_∞	Age≥75, High risk CVD*	SBP ≥130	SBP <120		
2018	Low risk [#]	SBP ≥160 or DBP ≥100	0		
CAN	Diabetes	SBP ≥130, DBP ≥80	<130/80		
С	All others	SBP ≥140, DBP ≥90	<140/9	0	
2	Older persons (≥65 years, ambulatory, non-institutionalized, community living adults)	SBP ≥130	SBP <13	30	
\sim	Adults with Clinical CVD or 10y ASCVD risk ≥ 10%, DM, CKD, HF, stable ischemic HD, PAD	≥130/80	<130/80		
ΥC	Adults - no clinical CVD & 10y ASCVD risk < 10%, or 2 nd stroke prevention	≥140/90	<130/80		
	Very high risk of CVD, established CAD	SBP ≥135 and/or DBP ≥85	Age ≥65: SBP 130-140, DBP 70-80	Age <65: SBP 120-130, DBP 70-80	
ESH/ESC 2018	Diabetes, CKD, HF, LVH, Low-moderate risk without CVD, renal disease or Hypertension Mediated Organ Damage after 3 to 6 months of lifestyle intervention	SBP ≥140 and/or DBP ≥90	Age ≥65^: <140/90 and >120/70; <130/80 ^{if tolerated} DM, age≥65: SBP 130-140, DBP 70-80	Age 18-65: <130/80 and >120/70 DM, age<65: SBP 120-130	
	All patients (including elderly age ≥80)	SBP ≥160 and/or DBP ≥100	Any age: CKD: <14 LVH: SB	40/80 P 120-130	

Hypertension in Older Adults

BP Targets

• What do the guidelines say??

[•] SO what do we do?

Back to the patient case....

- Measured BPs 3x / week for a month
 - Average BP was 100/64mmHg
 - Discussed discontinuing anti-hypertensive therapy entirely due to increased risk of falls and poor cardiac perfusion with this BP, patient and family were in agreement with the plan.
 - Also discontinued naproxen due to lack of pain symptoms.
- When BPs re-checked after discontinuation of the antihypertensive medication average readings were 130/80mmHg
 - Care home operator noted improved energy, more participation in activities following the medication changes.

Question...

What would you do if the BP goes up to 155/104 but the patient is asymptomatic?

- A) Nothing
- B) Restart the methyldopa
- C) Start HCTZ
- D) Start ramipril if the renal function is adequate

Patient Case #3 - Anticholinergics

- 72 year old male "Olaf"; new to your practice.
- Recently admitted to LTC & care team has noted issues with daytime drowsiness & constipation.
- Hx of Alzheimer's disease, hypertension, and diabetes.
- pleasant to talk to, though very disorganized. His son is present & mentions that his dad had been getting
 increasingly confused, and that this accelerated quite rapidly, necessitating his move to LTC from a
 personal care home.
- His recent labs show normal renal function and an A1C of 7.8%.
- Olaf's medication list includes:
 - Metformin 1000mg PO BID
 - Amlodipine 10mg PO QD
 - Perindopril/Indapamide 4mg/1.25mg PO QD
 - Oxybutynin 5mg PO OD
 - Risperidone 1mg PO QD
 - Senokot S 50mg/8.6mg PO QD

		OLINERGICS: Reference List of Drugs with Ar E, AVOID DRUGS WITH HIGH ANTICHOLINERGIC ACTIV		J Bareham BSP © <u>www.RxFiles.ca</u> May 2019
	Antibiotics	Antimuscarinics	Benzodiazepines	Muscle Relaxants
	ampicillin ✓ *ALL AVAILABLE AS cefoxitin X ✓ GENERIC clindamycin ✓ gentamicin (Olint & Sol'n NIHB covered) gentamicin (Olint & Sol'n NIHB covered) ✓ piperacillin X ⊗ ✓ vancomycin ≅ ✓ ✓	darifenacin ENABLEX ≅ Ø ⊠ fesoterodine TOVIAZ ≅ Ø ⊠ flavoxate URISPAS X ⊠ mirabegron ♦ MYRBETRIQ ≅ Ø oxybutynin DITROPAN (X ⊗ on XL only) ⊠ propiverine MICTORYL ™ ⊠ solifenacin VESICARE on SPDP ▼ ⊠ tolterodine I-tartrate DETROL LA on SPDP ▼ ⊠	alprazolam XANAX half-life: ~12 hr ✓ chlordiazepoxide LIBRIUM half-life: ~100 hr ⊗ ✓ clonazepam RIVOTRIL half-life: ~100 hr ⊗ ✓ clorazepate TRANXENE half-life: ~100 hr ⊗ ✓ diazepam VALIUM half-life: ~100 hr ⊗ ✓ flurazepam DALMANE half-life: ~100 hr ⊗ ✓ lorazepam XAIVAN half-life: ~100 hr ⊗ ✓ value DALMANE half-life: ~100 hr ⊗ ✓ lorazepam XAIVAN half-life: ~100 hr ⊗ ✓ value VERSED half-life: ~100 hr ⊗ ✓	baclofen LIORESAL (♣ on Intrathecal only) √ cyclobenzaprine FLEXERIL ♠ 𝔅 methocarbamol ROBAXIN OTC 𝔅 ⊗ orphenadrine NORFLEX OTC 𝔅 ⊗ tizanidine ZANAFLEX ♠ 𝔅 Baclofen is the preferred agent of the above listed muscle relaxants however, it does display moderate to high
	Antidepressants	trospium TROSEC = φ	oxazepam 🔅 SERAX half-life: ~8 hr 🗹	anticholinergic activity.
	amitriptyline ELAVIL clomiPRAMINE ANAFRANIL desipramine NORPRAMIN	Antiparkinsonian	temazepam ☆ RESTORIL half-life: ~11 hr ✓ triazolam HALCION half-life: ~2 hr ✓ Avoid long- & ultra-short acting agents in the elderly.	Opioids meperidine DEMEROL*Not for chronic use X ⊗ ⊠
TCA	doxepin SINEQUAN Imipramine imipramine TOFRANIL Imipramine nortriptyline AVENTYL Imipramine -less anticholinergic effects than amitriptyline & imipramine Imipramine trimipramine SURMONTIL Imipramine citalopram Imit CELEXA Imit CELEXA	benztropine mesylate COGENTIN ⊠ bromocriptine PARLODEL ✓ carbidopa/levodopa ☆ SINEMET ✓ entacapone COMTAN ✓ ethopropazine PARSITAN ⊠ pramipexole MIRAPEX ✓ procyclidine KEMADRIN ⊠	(Clonazepam ok, if long-acting required e.g. chronic anxiety) Cardiovascular Agents atenolol TENORMIN CAPOTEN Chlorthalidone GENERIC ONLY digoxin LANOXIN, TOLOXIN diltiazem ☆ CARDIZEM, TIAZAC disopyramide RYTHMODAN ⊠	codeine (會 on controlled release only, Ø, inj & liquid) Image: State of the state of t
CCDT	escitalopram * CIPRALEX Image: CIPRALEX fluoxetine PROZAC Image: CIPRALEX fluvoxamine LUVOX Image: CIPRALEX PARoxetine PAXIL Image: CIPRALEX sertraline * ZOLOFT Image: CIPRALEX	selegiline ELDEPRYL a▼ ✓ trihexyphenidyl ARTANE Antipsychotics aripiprazole ☆ ABILIFY a♡ & MAINTENAa▼ ✓	furosemide LASIX ✓ hydralazine APRESOLINE ✓ isosorbide ISORDIL ✓ metoprolol☆ LOPRESOR ✓ nifedipine ADALAT ✓	ZYTRAM XL X & <u>Preferred Alternatives:</u> acetaminophen X , NSAIDs (e.g. ibuprofen, naproxen)
	buPROPion ☆ WELLBUTRIN, ZYBAN Ø desvenlafaxine PRISTIQ X ⊗ Ø DULoxetine CYMBALTA	asenapine SAPHRIS (=-BPAD) ⊗ X chlorproMAZINE LARGACTIL ⊠ cloZAPine CLOZARIL ≅▼ ⊠	quinidine GENERIC ONLY X ⊗ ☑ triamterene DYRENIUM ☑ Gastrointestinal Agents	Respiratory Meds fluticasone/salmeterol ADVAIR = Ø theophylline THEOLAIR, UNIPHYL Ø
Other	moclobemide 🛪 MANERIX 🗹	flupentixol FLUANXOL ⊠ fluPHENAZine MODITEN ⊠ haloperidol ☆ HALDOL ✓ loxapine LOXAPAC ⊠ lurasidone ♦ LATUDA ≅ Ø X methotrimeprazine NOZINAN ⊠ OLANZapine ZYPREXA ⊠ paliperidone INVEGA (≅ Ø on injection only) ✓ pericyazine NEULEPTIL ⊠	belladonna GENERIC ONLY X ⊗ ⊠ chlordiazepoxide/clidinium LIBRAX X ⊗ ⊠ cimetidine TAGAMET ⊠ dicyclomine BENTYLOL ⊗ ⊠ diphenoxylate/atropine LOMOTIL ⊗ ⊠ famotidine ☆ PEPCID ^{OTC} & Rx ☑ loperamide IMODIUM ^{OTC} ☑	Miscellaneous busPIRone ♦ BUSPAR ✓ colchicine GENERIC ONLY ✓ dipyridamole PERSANTINE, AGGRENOX 🕿 ▼ ✓ doxylamine UNISOM X ⊗ ⊠ ketotifen ophthalmic ZADITOR 🕿 ⊗ ✓ lithium CARBOLITH, ✓

Spectrum of Anticholinergic Side-Effects

Mild	Moderate	Severe
 Drowsiness Fatigue Mild amnesia Inability to concentrate 	 Excitement Restlessness Confusion Memory impairment 	 Profound restlessness & disorientation, agitation Hallucinations, delirium Ataxia, muscle twitching, hyperreflexia, seizures Exacerbation of cognitive impairment (in patients with dementia)

Back to the patient case....

- Thorough medication review with geriatric pharmacist & conversation with his son did not find any indication for the oxybutynin, which was discontinued.
- Subsequent to this medication change care staff noted that Olaf's bowel movements were quite loose, and that he was stooling up to 4 times per day. His Senokot-S was discontinued, with resumption of his regular stooling pattern.
- Care staff had ongoing concerns about Olaf's level of daytime sedation, and his risperidone was gradually tapered and discontinued. There were no issues with responsive behaviours or aggression with the discontinuation of the risperidone.
- After all three medications were discontinued Olaf's son and care staff noticed that he was much more alert and engaged more readily in daily activities. His mobility improved and he was again able to mobilize with his walker without assistance from staff.

A final question....

82-year-old with history of anxiety & dementia, otherwise well. She lives at home with her family providing care. She has been taking amitriptyline because she reported trouble sleeping, as well as paroxetine for anxiety for many years. Currently, she is sleeping well but is displaying increased behaviours that are affecting the family's ability to care for her in her home (patient's wish). The family has come to you today asking if there is anything they can do to keep her in her own home longer. What might you suggest be done?

- A) Discontinue both amitriptyline and paroxetine as they are likely causing the problem
- B) Discontinue amitriptyline, then cross taper paroxetine to sertraline
- C) Discontinue the paroxetine, continue the amitriptyline
- D) Start discussing the need for an increased level of care (Personal Care Home/LTC).

Links to valuable resources

Clinical Frailty Score – Dalhousie University

https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale.html

Deprescribing Guidelines and Algorithms

https://deprescribing.org/resources/deprescribing-guidelines-algorithms/

Deprescribing Information Pamphlets for Patients – EMPOWER Brochures

https://deprescribing.org/resources/deprescribing-information-pamphlets/

Links to RxFiles Resources

Q&A - STATIN INTOLERANCE - MANAGEMENT CONSIDERATIONS

https://www.rxfiles.ca/RxFiles/uploads/documents/Lipid-Statin-Intolerance.pdf

Q&A - ASA: When to Prescribe?

<u>https://www.rxfiles.ca/RxFiles/uploads/documents/ASA-Q%20and%20A-When%20to%20prescribe.pdf</u>

Geri-RxFiles Table of Contents

https://www.rxfiles.ca/RxFiles/uploads/documents/Geri-RxFiles-Table-of-Contents-Links.pdf

RxFiles Newsletter – Geriatrics

 $\underline{https://www.rxfiles.ca/rxfiles/uploads/documents/Geriatrics-Newsletter\%20June\%202019.pdf}$